BPC-157 Dosage Protocols: Research Ranges, Frequency & Injection Guidance

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a naturally occurring protein found in gastric juice. Although it has no approved clinical indication as of this writing, BPC-157 has attracted sustained interest in preclinical research for its apparent tissue-healing and gastroprotective effects. This guide synthesizes the dosing parameters used across rodent and (where available) human-model studies so researchers can design informed protocols.

Typical Research Dose Ranges

The majority of peer-reviewed rodent studies use doses between 1 µg/kg and 10 µg/kg administered systemically. In absolute terms for a 200–300 g rat, this translates to roughly 0.2–3 µg per injection. When extrapolating to human-equivalent doses using body-surface-area scaling (dividing by the standard Km factor of 6.2 for humans vs. 3.1 for rats), a common research estimate for a 70–80 kg human subject falls in the range of 200–500 µg per day, though no controlled human pharmacokinetic data exists to validate this extrapolation with precision.

Some protocols referenced in anecdotal research communities use 250 µg twice daily (500 µg total), while others report starting at 200 µg once daily and titrating upward based on response. Researchers should note that BPC-157 studies in animals frequently use systemically administered doses rather than oral, and the bioavailability comparison between routes is not well-characterized.

Body-Weight Scaling and Frequency

Body-surface-area (BSA) scaling is generally preferred over simple mg/kg scaling when translating animal doses to human equivalents, particularly for peptides. The Reagan-Shaw method (human equivalent dose = animal dose × animal Km / human Km) places the commonly cited rat dose of 10 µg/kg at roughly 1.6 µg/kg for humans — approximately 112–130 µg for a 70–80 kg subject. Most community research protocols empirically run higher than this strict BSA figure.

Regarding frequency, the published animal literature most commonly uses once-daily administration. Some researchers use split dosing (morning and evening) on the rationale that BPC-157 has a short half-life in vivo, though no published human pharmacokinetic data confirms whether this confers meaningful benefit. Daily injections are the most widely replicated protocol.

Injection Site Rotation Rationale

Subcutaneous (SC) injection sites should be rotated systematically to prevent localized lipohypertrophy — the accumulation of fibrous or fatty tissue that can impair absorption and cause cosmetic changes. Common rotation maps divide the abdomen into quadrants, cycling daily: right upper, left upper, left lower, right lower. Thigh and upper-arm sites can also be used. Intramuscular (IM) injection into the deltoid, vastus lateralis, or gluteus medius follows similar rotation principles.

Beyond absorption efficiency, site rotation reduces the local inflammatory burden at any single injection point, which matters for peptides that may be themselves anti-inflammatory — consistent tissue integrity ensures reproducible delivery. Using a 27–29 gauge, 0.5-inch needle for SC administration is standard practice.

Research Duration: 4–8 Weeks

In the published rodent literature, BPC-157 protocols span durations from a single injection to chronic 30-day courses depending on the endpoint studied. Acute wound-healing studies often run 7–14 days; tendon and ligament repair models typically run 4 weeks; inflammatory bowel models have used continuous administration for 4–8 weeks. Community research protocols commonly mirror the 4–8 week window, after which a rest period of similar length is typically incorporated before resuming.

No long-term human safety data exists. Researchers should familiarize themselves with the available toxicology profiles from animal studies, which have not identified significant organ toxicity at doses used in healing models, but which cannot substitute for properly controlled clinical data.

Sourcing and Purity Verification

BPC-157 is supplied as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water (BAC water) prior to injection. Researchers should verify purity through a Certificate of Analysis (COA) showing HPLC purity ≥98% and mass-spec confirmation of molecular weight (MW 1419.53 g/mol). See our guide to reading a COA at /guides/reading-a-coa for a full breakdown of what to look for.